Cover Image
市場調查報告書

潰瘍性大腸炎的全球市場:2016∼2020年

Global Ulcerative Colitis Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 357712
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
潰瘍性大腸炎的全球市場:2016∼2020年 Global Ulcerative Colitis Market 2016-2020
出版日期: 2016年05月02日 內容資訊: 英文 67 Pages
簡介

潰瘍性大腸炎是大腸、直腸發炎性疾病的一種,會在大腸或直腸最深處發炎或形成潰瘍。常見的一般性症狀有腹部痙攣,腹瀉,直腸出血等。全球潰瘍性大腸炎市場在2016∼2020年這段期間預測將以年複合成長率6.6%擴大。

本報告提供全球潰瘍性大腸炎市場現狀與到2020年前的成長預測,彙整市場趨勢與課題,各地區趨勢,主要供應商簡介等資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • 對疾病的認識
  • 病因
  • 流行病學
  • 症狀
  • 診斷與檢查
  • 治療
  • 預後
  • 經濟負擔
  • 給付方案

第6章 開發平台分析

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各分子類型市場區隔

  • 生技藥品
  • 小分子
  • 潰瘍性大腸炎藥物市場上生技藥品市場區隔
  • 潰瘍性大腸炎藥物市場上小分子市場區隔

第9章 各劑型市場區隔

  • 固態
  • 液體

第10章 各給藥途徑市場區隔

  • 口服
  • 非口服

第11章 各地區市場區隔

  • 各地區市場
  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第12章 推動市場的要素

  • 患者支援計劃的增加
  • 未滿足需求高
  • 開發平台候補的初步認証

第13章 促進要素的影響

第14章 市場課題

  • 藥物成本高
  • 專利的執行
  • 藥物的副作用
  • 不明的病因

第15章 促進要素與課題的影響

第16章 市場趨勢

第17章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • AbbVie
  • Janssen Biotech
  • Merck
  • 武田製藥工業株式會社
  • 其他值得注意的供應商

第18章 附錄

第19章 關於Technavio

圖表

目錄
Product Code: IRTNTR8159

About Ulcerative Colitis

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that affects the colon and rectum. Inflammation and ulcers are formed in the innermost lining of the colon and rectum, resulting in the production of pus and mucous. Based on the extent of inflammation and the location, ulcerative colitis can be of different types: ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. Abdominal cramps, diarrhea, and rectal bleeding are among the common symptoms observed in individuals with the disease. Medications such as 5-aminosalicylates, steroids, purine analogs, immunomodulators, and biologics are used to treat the disease.

Technavio's analysts forecast the global ulcerative colitis market to grow at a CAGR of 6.6% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global ulcerative colitis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used to treat ulcerative colitis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Ulcerative Colitis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Janssen Biotech
  • Merck
  • Takeda Pharmaceuticals

Other Prominent Vendors

  • Abbott
  • Ajinomoto Pharmaceuticals
  • Amgen
  • Arena Pharmaceuticals
  • AstraZeneca
  • Astellas Pharma
  • Avaxia Biologics
  • BioLineRx
  • Celgene
  • Cosmo Pharmaceuticals
  • Eisai
  • Ferring Pharmaceuticals
  • Galapagos
  • Genentech
  • Gilead Sciences
  • GlaxoSmithKline
  • Hutchison Medi Pharma
  • Immune Pharmaceuticals
  • InDex Pharmaceuticals
  • Kaken Pharmaceutical
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Lipid Therapeutics
  • Meda
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Morphotek
  • Nestle
  • Pfizer
  • Procter & Gamble
  • Qu Biologics
  • Receptos
  • Salix Pharmaceuticals
  • Shield Therapeutics
  • Shire Pharmaceuticals
  • Sterna Biologicals
  • Tillotts Pharma
  • TopiVert
  • UCB
  • Zeria Pharmaceutical

Market driver

  • Increase in patient assistance programs
  • For a full, detailed list, view our report

Market challenge

  • Patent expiries
  • For a full, detailed list, view our report

Market trend

  • Rising use of biologics
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Etiology
  • Epidemiology
  • Symptoms
  • Diagnosis and testing
  • Treatment
  • Prognosis
  • Economic burden
  • Reimbursement scenario

PART 06: Pipeline analysis

  • Z-206
  • MD-0901
  • TP05
  • Stelara
  • Etrolizumab
  • Xeljanz
  • HMPL-004
  • Kappaproct
  • AJG511
  • AJM300

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by molecule type

  • Biologics
  • Small molecules
  • Biologics segment in ulcerative colitis drugs market
  • Small molecules segment in ulcerative colitis drugs market

PART 09: Market segmentation by dosage form

  • Solid
  • Liquid

PART 10: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 11: Geographical segmentation

  • Global ulcerative colitis drugs market by geography 2015-2020
  • Ulcerative colitis drugs market in Americas
  • Ulcerative colitis drugs market in EMEA
  • Ulcerative colitis drugs market in APAC

PART 12: Market drivers

  • Increase in patient assistance programs
  • High unmet needs
  • Tentative approval of candidates in pipeline

PART 13: Impact of drivers

PART 14: Market challenges

  • High cost of drugs
  • Patent expiries
  • Adverse effects of drugs
  • Unknown disease etiology

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Growing public awareness
  • Rising use of biologics
  • Emergence of biosimilars
  • Strategic alliances

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • AbbVie
  • Janssen Biotech
  • Merck
  • Takeda Pharmaceuticals
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Causes of ulcerative colitis
  • Exhibit 03: Symptoms of ulcerative colitis
  • Exhibit 04: Diagnostic approach for ulcerative colitis
  • Exhibit 05: Treatment options for ulcerative colitis
  • Exhibit 06: Treatment guidelines of ulcerative colitis based on severity
  • Exhibit 07: Surgical procedures to treat ulcerative colitis
  • Exhibit 08: Global ulcerative colitis drugs market: Pipeline portfolio
  • Exhibit 09: Global ulcerative colitis drugs market 2015-2020 ($ billions)
  • Exhibit 10: Snapshot of global ulcerative colitis drugs market
  • Exhibit 11: Five forces analysis
  • Exhibit 12: Global ulcerative colitis drugs market by molecule type
  • Exhibit 13: Global ulcerative colitis drugs market by molecule type 2015
  • Exhibit 14: Biologics segment in ulcerative colitis drugs market 2015-2020 ($ billions)
  • Exhibit 15: Small molecules segment in ulcerative colitis drugs market 2015-2020 ($ billions)
  • Exhibit 16: Global ulcerative colitis drugs market by dosage form
  • Exhibit 17: Global ulcerative colitis drugs market by route of administration
  • Exhibit 18: Global ulcerative colitis drugs market segment by geography 2015
  • Exhibit 19: Ulcerative colitis drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 20: Ulcerative colitis drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 21: Ulcerative colitis drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 22: Ulcerative colitis drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Impact of drivers and challenges
  • Exhibit 25: Global ulcerative colitis drugs market share analysis 2015
  • Exhibit 26: YoY revenue comparison of top drugs for ulcerative colitis 2011-2014 ($ millions)
  • Exhibit 27: AbbVie: Product segmentation by revenue 2014
  • Exhibit 28: AbbVie: Product segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 29: AbbVie: Geographical segmentation by revenue 2014
  • Exhibit 30: AbbVie: YoY growth and revenue of Humira 2012-2014 ($ billions)
  • Exhibit 31: AbbVie: Key takeaways
  • Exhibit 32: Janssen Biotech: YoY growth and revenue of Remicade 2012-2014 ($ millions)
  • Exhibit 33: Janssen Biotech: YoY growth and revenue of Simponi/Simponi ARIA 2012-2014 ($ millions)
  • Exhibit 34: Janssen Biotech: Key takeaways
  • Exhibit 35: Merck: Business segmentation by revenue 2014
  • Exhibit 36: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 37: Merck: Geographical segmentation by revenue 2014
  • Exhibit 38: Merck: YoY growth and revenue of Remicade 2012-2014 ($ millions)
  • Exhibit 39: Merck: YoY growth and revenue of Simponi 2012-2014 ($ millions)
  • Exhibit 40: Merck: Key takeaways
  • Exhibit 41: Takeda Pharmaceuticals: Business segmentation by revenue 2014
  • Exhibit 42: Takeda Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2014
  • Exhibit 44: Takeda Pharmaceuticals: Key takeaways
Back to Top